BioCentury
ARTICLE | Top Story

Sangstat settles with Novartis

July 27, 2000 7:00 AM UTC

SANG said it settled cyclosporine patent litigation with Novartis (SWX:NOVN; NVS) that had been ongoing in the U.S. and U.K. The settlement comes two weeks after SANG withdrew from the market its SangCya generic cyclosporine oral solution, the product at issue in the dispute (see BioCentury, July 17). SANG continues to co-market GenGraf cyclosporine capsules with Abbott Laboratories. No litigation is ongoing related to GenGraf. ...